EGFR and Hyponatremia: Interestingly, in NSCLC patients treated with the EGFR inhibitor erlotinib a multivariate analysis revealed that hyponatremia was an independent predictive factor of non-response to therapy, in the same way as a poor performance status and the absence of EGFR mutations in the tumoral tissue [81].